KMDA - Kamada Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.8300
-0.1500 (-3.01%)
At close: 04:00PM EDT
4.8300 0.00 (0.00%)
After hours: 05:36PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close4.9800
Open4.9340
Bid4.8300 x 1400
Ask4.9100 x 900
Day's Range4.8299 - 4.9340
52 Week Range3.7200 - 5.7200
Volume25,065
Avg. Volume33,217
Market Cap217.56M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0500
Earnings DateAug 15, 2023 - Aug 21, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KMDA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Zacks Small Cap Research

    KMDA: 1Q23 Revenues of $30.7 Million; Continue to Expect 2023 Revenues of $138 Million to $146 Million…

    By David Bautz, PhD NASDAQ:KMDA READ THE FULL KMDA RESEARCH REPORT Financial Update On May 24, 2023, Kamada Ltd. (NASDAQ:KMDA) announced financial results for the first quarter of 2023. Kamada reported revenues of $30.7 million, which was a 9% increase over the first quarter of 2022. The revenue consisted of $24.1 million from proprietary products and $6.6 million from the distribution business.

  • GlobeNewswire

    Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance

    Total Revenues for First Quarter of 2023 were $30.7 Million, Up 9% Year-over-YearFirst Quarter 2023 EBITDA of $3.8 Million, Increase of 16% Year-over-YearSolid First Quarter Results and Expected Continued Momentum Supported by Multiple Growth Drivers Anticipated to Drive Full-Year 2023 EBITDA Growth of Over 30% Year-over-YearAnnounced $60 Million Private Placement with FIMI Opportunity FundsReceived FDA Approval to Manufacture CYTOGAM® at the Company’s Israeli Facility; Expected to Positively Im

  • GlobeNewswire

    Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary

    REHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (“Kamada” or the “Company”), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that following the recently announced $60 million private placement with the FIMI Opportunity Funds, which is expected to contribute to accelerating the growth o

  • GlobeNewswire

    Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds

    Funding to Support Kamada’s Growth Plans and Execution of Strategic Business Development OpportunitiesREHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (“Kamada” or the “Company”), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it has entered into a share purchase agreement (the “P

  • GlobeNewswire

    Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023

    REHOVOT, Israel and HOBOKEN, N.J., May 17, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter ended March 31, 2023, prior to the open of the U.S. financial markets on Wednesday, May 24, 2023. Kamada management will host an investm

  • GlobeNewswire

    Kamada Announces Receipt of Marketing Authorization for Glassia® for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland

    Switzerland is the first European country to approve Glassia®, which received U.S. FDA approval in 2010Glassia will be commercialized by IDEOGEN AG in Switzerland and the therapy is expected to be available to patients and providers during the second half of 2023The current Alpha-1 Antitrypsin Deficiency (AATD) market in Switzerland is estimated to be over $15 million annually REHOVOT, Israel and HOBOKEN, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commerc

  • GlobeNewswire

    Kamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company’s Facility in Israel

    Sales of CYTOGAM® Highest Among Four IgG Products Acquired in November 2021 with Approximately $23 Million in Revenues in 2022, and Gross Margins Over 50%Approval to Manufacture CYTOGAM at Kamada’s Facility to Positively Impact Plant Utilization and Efficiency REHOVOT, Israel and HOBOKEN, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that

  • Zacks Small Cap Research

    KMDA: 2022 Revenue of $129 Million; Expected 2023 Revenues of $138 Million to $146 Million and Continued Positive Operating Cash Flow…

    By David Bautz, PhD NASDAQ:KMDA READ THE FULL KMDA RESEARCH REPORT Financial Update On March 15, 2023, Kamada Ltd. (NASDAQ:KMDA) announced financial results for the fourth quarter and full year 2022 and provided a business update. Kamada reported revenues of $129.3 million, which met the company’s previously announced guidance, and was a 25% increase compared to fiscal year 2021. The increase was

  • Insider Monkey

    Kamada Ltd. (NASDAQ:KMDA) Q4 2022 Earnings Call Transcript

    Kamada Ltd. (NASDAQ:KMDA) Q4 2022 Earnings Call Transcript March 15, 2023 Operator: Greetings. Welcome to the Kamada Ltd. Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. Please note, this conference is being recorded. At this time, […]

  • GlobeNewswire

    Kamada Issues 2023 CEO Letter to Shareholders

    REHOVOT, Israel and HOBOKEN, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today issued a Letter to Shareholders from Amir London, Chief Executive Officer. Dear Shareholders, Colleagues and Business Partners: The recently completed 2022 year was a transformational period for Ka

  • GlobeNewswire

    Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth

    Total Revenues for Fiscal Year 2022 of $129.3 Million Represented Growth of 25% Compared to Fiscal Year 2021; Fourth Quarter 2022 Revenues of $45.4 Million Represented a 44% Increase Year-over-YearFiscal Year 2022 EBITDA of $17.8 million, Represented Margins of 14%, and a 3x Increase Over Fiscal Year 2021Recorded Highest Annual Operating Cash Flow in Kamada's History of $28.6 Million in Fiscal Year 2022; $34.3 Million Cash Position as of December 31, 2022, Nearly Double Cash Position at Year-End

  • GlobeNewswire

    Kamada to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 15, 2023

    REHOVOT, Israel and HOBOKEN, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2022, prior to the open of the U.S. financial markets on Wednesday, March 15, 2023. Kamada managemen

  • Zacks Small Cap Research

    KMDA: Initiating Coverage on Kamada Ltd; A Commercial Stage Biopharmaceutical Company with a Portfolio of Marketed Products…

    By David Bautz, PhD NASDAQ:KMDA READ THE FULL KMDA RESEARCH REPORT Initiating Coverage We are initiating coverage of Kamada Ltd. (NASDAQ:KMDA) with a valuation of $14.00. Kamada is a vertically integrated biopharmaceutical company with a marketed portfolio of products indicated for rare and serious conditions, focused on specialty plasma-derived therapeutics. The company has two core segments:

  • GlobeNewswire

    Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company’s Facility in Israel

    FDA Approval Currently Expected by Mid-2023Sales of CYTOGAM® Highest Among Four IgG Products Acquired in November 2021, with Gross Margins Over 50%Ability to Manufacture CYTOGAM at Kamada’s Facility to Positively Impact Plant Utilization and Efficiency REHOVOT, Israel and HOBOKEN, N.J. , Jan. 04, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it ha

  • Zacks

    Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day

    Mesa Labs and Eldorado Gold are part of the Zacks Bull and Bear of the Day article.

  • Zacks

    3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

    We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.

  • Insider Monkey

    Kamada Ltd. (NASDAQ:KMDA) Q3 2022 Earnings Call Transcript

    Kamada Ltd. (NASDAQ:KMDA) Q3 2022 Earnings Call Transcript November 22, 2022 Kamada Ltd. beats earnings expectations. Reported EPS is $0.01, expectations were $-0.03. Operator: Greetings. Welcome to the Kamada Ltd., Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. Please […]

  • GlobeNewswire

    Kamada Announces Planned Transition of Chief Financial Officer

    REHOVOT, Israel and HOBOKEN, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that its Chief Financial Officer (CFO), Chaime Orlev, will transition out of his role to pursue other opportunities, effective March 15, 2023, following the expected filing date of Kamada’s Annual Report on Form 20-F. Kamada has a search underway to identify a suc

  • Zacks

    Wave Life Sciences (WVE) Up 26% on Collaboration With GSK

    Wave Lifesciences (WVE) signs a four-year research collaboration with GSK to advance discovery and development of oligonucleotide therapeutics focusing on novel genetic targets

  • Zacks

    Valneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data

    Persistence data from a mid-stage study showed that Valneva's (VALN) Lyme disease vaccine elicited antibody levels which remained above baseline six months after completing dose administration in children and adults.

  • Zacks

    New Strong Buy Stocks for November 28th

    KMDA, SLCA and FTNT have been added to the Zacks Rank #1 (Strong Buy) List on November 28, 2022.

  • PR Newswire

    AcuCort signs its first commercial agreement for the company's drug Zeqmelit™

    AcuCort AB (publ) (Spotlight Stock Market: ACUC) today announces that the company has signed an exclusive commercial agreement with the global biopharmaceutical company Kamada Ltd., (NASDAQ: KMDA; TASE: KMDA.TA). The agreement gives Kamada the exclusive right to the marketing and sales as well as the distribution of AcuCort's drug Zeqmelit™ for, among other things, the treatment of acute allergy on the Israeli market.

  • Zacks

    Kamada (KMDA) Q3 Earnings and Revenues Top Estimates

    Kamada (KMDA) delivered earnings and revenue surprises of 433.33% and 8.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Kamada Reports Strong Third Quarter Financial Results Demonstrating Successful Strategic Transition and Reiterates 2022 Financial Guidance

    Third Quarter 2022 Revenues of $32.2 Million, a 40% Increase Compared to Prior Year Period; Reaping the Benefits of the Acquired IgG PortfolioStrong Results Represent Completion of the Company’s Strategic Transformation into a Diversified Commercial Entity with Multiple Growth DriversAdjusted EBITDA for the Third Quarter was $6.0 Million, or 19% Margin and for First Nine Months was $10.6 Million or 13% Margin, Within Annual Guidance, and Representing 58% Increase Year-over-YearGenerated Operatin

  • GlobeNewswire

    Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2022 Financial Results and Host Conference Call on November 22, 2022

    REHOVOT, Israel, and HOBOKEN, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today announced that it will release financial results for the third quarter and first nine months ended September 30, 2022, prior to the open of the U.S. financial markets on Tuesday, November 22, 2022. Kamada management will host an investment community conference call on Tuesday, Nov